{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T10:07:55Z","timestamp":1780308475284,"version":"3.54.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019832","name":"Galapagos NV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a need for improved disease-targeting therapies for autosomal dominant polycystic kidney disease (ADPKD). This study evaluated the efficacy and safety of GLPG2737, a cystic fibrosis transmembrane conductance regulator inhibitor, in ADPKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MANGROVE (NCT04578548) was an exploratory, phase 2a, proof-of-concept, randomized, multicenter study. Eligible patients were aged 18\u201350 years with rapidly progressing, typical ADPKD. Patients were randomly assigned (2:1) to double-blind treatment with once-daily, oral GLPG2737 150\u00a0mg, or placebo for 52 weeks. This was followed by a 52-week open-label extension (OLE) period, in which all patients received GLPG2737. Both periods had a 4-week follow-up period without treatment. Primary endpoints were the mean percentage change from baseline in height-adjusted total kidney volume (htTKV), and frequency and severity of treatment-emergent adverse events (TEAEs). A key secondary endpoint was the mean change from baseline in estimated glomerular filtration rate (eGFR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 89 patients were screened between 10 November 2020 and 2 March 2023; 66 patients received treatment (GLPG2737, n = 44; placebo, n = 22), and 61 patients completed the double-blind period (GLPG2737, 41\/44; placebo, 20\/22). Changes in htTKV from baseline to week 52 did not differ between GLPG2737 and placebo {GLPG2737: 8.2% [95% confidence interval (CI 6.0%, 10.4%); placebo: 9.2% [95% CI 6.1%, 12.4%]; between-treatment difference: \u22120.91% [95% CI \u22124.34%, 2.64%],\u00a0P = .61}. There were no life-threatening TEAEs or deaths. Similar proportions of patients had treatment-related TEAEs in the GLPG2737 (13\/44, 30%) and placebo (6\/22, 27%) groups. Mean between-treatment difference for change in eGFR from baseline to week 52 (GLPG2737 vs placebo) was not significant \u22122.31 ml\/min\/1.73 m2 (95% CI \u22125.64, 1.02; P =\u00a0.17).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, GLPG2737 was generally well tolerated. However, GLPG2737 150\u00a0mg once daily was not efficacious in reducing htTKV or slowing eGFR decline over 52 weeks compared with placebo. Thus, the study was terminated early after the double-blind period; results from the OLE period are reported in brief.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfag093","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:45:09Z","timestamp":1779882309000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of the cystic fibrosis transmembrane conductance regulator inhibitor GLPG2737 for autosomal dominant polycystic kidney disease: phase 2a MANGROVE study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3223-0906","authenticated-orcid":false,"given":"Ron T","family":"Gansevoort","sequence":"first","affiliation":[{"name":"University Medical Centre Groningen, University of Groningen Department of Nephrology, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Hueso","sequence":"additional","affiliation":[{"name":"Bellvitge University Hospital and Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat Department of Nephrology, , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[{"name":"University of Naples Federico II Department of Public Health, , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinia","family":"Van\u00a0den\u00a0Bergh","sequence":"additional","affiliation":[{"name":"Clinical Development (R&D), Galapagos NV , Mechelen ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Muller","sequence":"additional","affiliation":[{"name":"Clinical Development (R&D), Galapagos NV , Mechelen ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lazaryan","sequence":"additional","affiliation":[{"name":"Biostatistics, Galapagos SASU , Romainville ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M","family":"Fieuw","sequence":"additional","affiliation":[{"name":"Clinical Development (R&D), Galapagos NV , Mechelen ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W\u0142adys\u0142aw","family":"Su\u0142owicz","sequence":"additional","affiliation":[{"name":"Jagiellonian University Department of Nephrology, , Krak\u00f3w ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"2026060105415483400_bib1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2026060105415483400_bib2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le\u00a0Gall","year":"2019","journal-title":"Lancet"},{"key":"2026060105415483400_bib3","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2215\/CJN.03960318","article-title":"Recent advances in the management of autosomal dominant polycystic kidney disease","volume":"13","author":"Chebib","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026060105415483400_bib4","doi-asserted-by":"publisher","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","article-title":"Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2014an analysis of data from the ERA-EDTA Registry","volume":"29","author":"Spithoven","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2026060105415483400_bib5","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"2026060105415483400_bib6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/DHPS.S338050","article-title":"Clinical utility and tolerability of tolvaptan in the treatment of autosomal dominant polycystic kidney disease (ADPKD)","volume":"14","author":"Raina","year":"2022","journal-title":"Drug Healthc Patient Saf"},{"key":"2026060105415483400_bib7","doi-asserted-by":"publisher","first-page":"109703","DOI":"10.1016\/j.cellsig.2020.109703","article-title":"Targeting chloride transport in autosomal dominant polycystic kidney disease","volume":"73","author":"Jouret","year":"2020","journal-title":"Cell Signalling"},{"key":"2026060105415483400_bib8","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1681\/ASN.2007070828","article-title":"Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease","volume":"19","author":"Yang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2026060105415483400_bib9","doi-asserted-by":"publisher","first-page":"11513","DOI":"10.1074\/jbc.RA118.001846","article-title":"A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector","volume":"293","author":"Yanda","year":"2018","journal-title":"J Biol Chem"},{"key":"2026060105415483400_bib10","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1681\/ASN.2006030295","article-title":"Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to cAMP stimulation with cystic fibrosis transmembrane conductance regulator\/Na","volume":"17","author":"Magenheimer","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2026060105415483400_bib11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S0272-6386(98)70072-1","article-title":"Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease","volume":"32","author":"O'Sullivan","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2026060105415483400_bib12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/joneph\/19.4.529","article-title":"Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis","volume":"19","author":"Xu","year":"2006","journal-title":"J Nephrol"},{"key":"2026060105415483400_bib13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3389\/fphar.2019.00514","article-title":"Identification of GLPG\/ABBV-2737, a novel class of corrector, which exerts functional synergy with other CFTR modulators","volume":"10","author":"de\u00a0Wilde","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026060105415483400_bib14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/ppul.23840","article-title":"Safety, tolerability and pharmacokinetics of single and multiple doses of GLPG2737, a novel CFTR corrector molecule, in healthy volunteers","volume":"52","author":"Brearley","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"2026060105415483400_bib15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jcf.2019.09.006","article-title":"GLPG2737 in lumacaftor\/ivacaftor-treated CF subjects homozygous for the F508del mutation: a randomized phase 2A trial (PELICAN)","volume":"19","author":"van\u00a0Koningsbruggen-Rietschel","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026060105415483400_bib16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000545614","article-title":"GLPG2737, a CFTR inhibitor, prevents cyst growth in preclinical models of autosomal dominant polycystic kidney disease","volume":"56","author":"Dumont","year":"2025","journal-title":"Am J Nephrol"},{"key":"2026060105415483400_bib17","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1","volume":"343","author":"Ravine","year":"1994","journal-title":"Lancet"},{"key":"2026060105415483400_bib18","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s10278-017-9978-1","article-title":"Performance of an artificial multi-observer deep neural network for fully automated segmentation of polycystic kidneys","volume":"30","author":"Kline","year":"2017","journal-title":"J Digit Imaging"},{"key":"2026060105415483400_bib19","article-title":"MedDRA Version 25.1","author":"International Council for Harmonisation (ICH)","year":"2022"},{"key":"2026060105415483400_bib20","doi-asserted-by":"publisher","first-page":"10260","DOI":"10.1021\/bi060490t","article-title":"CFTR Expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis","volume":"45","author":"Painter","year":"2006","journal-title":"Biochemistry"},{"key":"2026060105415483400_bib21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2215\/CJN.06300615","article-title":"Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial","volume":"11","author":"Torres","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026060105415483400_bib22","doi-asserted-by":"publisher","DOI":"10.11613\/BM.2021.010502","article-title":"Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies","volume":"31:","author":"Serdar","year":"2021","journal-title":"Biochem Med (Zagreb)"},{"key":"2026060105415483400_bib23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijrobp.2021.07.1700","article-title":"An overview of phase 2 clinical trial designs","volume":"112","author":"Torres-Saavedra","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060105415483400_bib24","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1681\/ASN.2016111232","article-title":"Bosutinib versus placebo for autosomal dominant polycystic kidney disease","volume":"28","author":"Tesar","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026060105415483400_bib25","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"key":"2026060105415483400_bib26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3390\/microorganisms7120692","article-title":"Salivary biomarkers and oral microbial load in relation to the dental status of adults with cystic fibrosis","volume":"7","author":"Pawlaczyk-Kamie\u0144ska","year":"2019","journal-title":"Microorganisms"},{"key":"2026060105415483400_bib27","doi-asserted-by":"publisher","first-page":"31237","DOI":"10.1038\/s41598-024-82535-z","article-title":"Inhibiting CFTR through inh-172 in primary neutrophils reveals CFTR-specific functional defects","volume":"14","author":"Da\u00a0Silva\u00a0Cunha","year":"2024","journal-title":"Sci Rep"},{"key":"2026060105415483400_bib28","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1182\/blood.2021014699","article-title":"Neutrophil dysfunction in the pathogenesis of cystic fibrosis","volume":"139","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"2026060105415483400_bib29","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1021\/acs.jmedchem.3c01790","article-title":"Discovery of GLPG2737, a potent type 2 corrector of CFTR for the treatment of cystic fibrosis in combination with a potentiator and a type 1 co-corrector","volume":"67","author":"Pizzonero","year":"2024","journal-title":"J Med Chem"},{"key":"2026060105415483400_bib30","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag093\/68411102\/gfag093.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag093\/68411102\/gfag093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:42:04Z","timestamp":1780306924000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article\/doi\/10.1093\/ndt\/gfag093\/8696158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag093","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"article-number":"gfag093"}}